Does 12-month treatment with GLP-1RA, SGLT-2i, or their combination improve endothelial glycocalyx, arterial function, and myocardial work index compared to insulin in patients with type 2 diabetes mellitus?
In patients with type 2 diabetes, a 12-month combined therapy of GLP-1RA and SGLT-2i provides superior improvements in vascular markers and cardiac work compared to either agent alone or insulin.
<0.05). Conclusions Twelve-month treatment with GLP-1RA, SGLT-2i, and their combination showed a greater improvement of vascular markers and effective cardiac work than insulin treatment in type 2 diabetes mellitus. The combined therapy as second line was superior to either insulin or GLP-1RA and SGLT-2i separately. Registration URL: https://www.clinicaltrials.gov. Unique identifier: NCT03878706.
Ikonomidis et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: